3B Blackbio Dx Limited Stock Price Today (NSE: 3BBLACKBIO)
Fundamental Score
3B Blackbio Dx Limited Share Price — Live NSE/BSE Price, Fundamentals & Analysis
3B Blackbio Dx Limited share price today is ₹1262.40, up +9.93% on NSE/BSE as of 25 August 2026. 3B Blackbio Dx Limited (3BBLACKBIO) is a Small-cap company in the Healthcare Service Provider sector with a market capitalisation of ₹1.08K (Cr). The 52-week high for 3BBLACKBIO share price is ₹1750.00 and the 52-week low is ₹1083.50.
3B Blackbio Dx Limited Share Price Chart — NSE/BSE Historical Performance
3B Blackbio Dx Limited share price chart: -8.63% return over the past month. 52-week high ₹1750.00, 52-week low ₹1083.50.
3B Blackbio Dx Limited — Last 10 Trading Days
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| ₹1261.50 | ₹1279.00 | ₹1230.10 | ₹1262.40 | 11.00K (Cr) | |
| ₹1154.20 | ₹1167.80 | ₹1142.00 | ₹1148.40 | 7.53K (Cr) | |
| ₹1200.00 | ₹1200.00 | ₹1155.90 | ₹1173.95 | 3.35K (Cr) | |
| ₹1261.45 | ₹1262.00 | ₹1220.00 | ₹1222.45 | 757.00 (Cr) | |
| ₹1219.90 | ₹1261.05 | ₹1195.30 | ₹1246.65 | 1.56K (Cr) | |
| ₹1248.05 | ₹1248.05 | ₹1194.65 | ₹1206.45 | 991.00 (Cr) | |
| ₹1244.95 | ₹1250.00 | ₹1207.25 | ₹1244.00 | 1.71K (Cr) | |
| ₹1208.15 | ₹1218.10 | ₹1200.90 | ₹1208.85 | 424.00 (Cr) | |
| ₹1216.35 | ₹1226.10 | ₹1203.05 | ₹1204.00 | 1.00K (Cr) | |
| ₹1242.55 | ₹1242.55 | ₹1201.50 | ₹1206.55 | 765.00 (Cr) |
3B Blackbio Dx Limited — Last 12 Months Price History
| Month | Open | High | Low | Close | Change |
|---|---|---|---|---|---|
| ₹1250.05 | ₹1279.00 | ₹1142.00 | ₹1262.40 | +0.99% | |
| ₹1186.80 | ₹1321.60 | ₹1130.30 | ₹1248.10 | +5.17% | |
| ₹1179.10 | ₹1309.45 | ₹1083.50 | ₹1168.60 | -0.89% | |
| ₹1200.65 | ₹1413.00 | ₹1177.00 | ₹1244.05 | +3.61% | |
| ₹1151.00 | ₹1409.00 | ₹1110.00 | ₹1206.60 | +4.83% | |
| ₹1302.00 | ₹1404.70 | ₹1120.00 | ₹1126.00 | -13.52% | |
| ₹1643.95 | ₹1720.00 | ₹1323.05 | ₹1351.50 | -17.79% | |
| ₹1400.05 | ₹1750.00 | ₹1370.00 | ₹1667.45 | +19.10% | |
| ₹1319.90 | ₹1464.00 | ₹1151.00 | ₹1404.95 | +6.44% | |
| ₹1374.00 | ₹1439.00 | ₹1175.30 | ₹1286.30 | -6.38% | |
| ₹1374.80 | ₹1453.00 | ₹1311.00 | ₹1377.85 | +0.22% | |
| ₹1431.00 | ₹1500.00 | ₹1310.00 | ₹1374.80 | -3.93% |
AI Research Briefing
Powered by Gemini · 2026-04-17
Decent growth story but rich valuation and micro-cap risk limit upside.
WHAT'S HAPPENING NOW (last 2-4 weeks)
No major catalysts found after live search. Trading window closed on April 1st, 2026, ahead of FY26 results. Investors await the board meeting announcement for FY26 results.
CORE STORY (THE REAL GAME)
3B Blackbio is a play on the growth of molecular diagnostics in India, riding the wave of increased healthcare spending and a shift towards preventative care. The Coris BioConcept acquisition signals a move towards global expansion and product diversification.
- Strong revenue growth in 9M FY26
- Expansion into global markets with Coris BioConcept acquisition
- Guidance for 10-15% revenue and EBITDA growth
- Strong FY26 results
- Successful integration of Coris BioConcept
- Entry into the US market
- Micro-cap liquidity risk
- Rich valuation
- Integration risk with Coris BioConcept
FII decreased by 0.06% and DII increased by 0.06% [cite: brief].
Healthcare spending in India is increasing, providing a tailwind for diagnostic companies.
Yes - Free Cash Flow 5Y: ₹218.07 Cr [cite: brief]
Expect continued growth in revenue and profitability, driven by expansion in India and globally. Key risk is the successful integration of Coris BioConcept.
Primary Thesis Risk
Failure to integrate Coris BioConcept acquisition will destroy the thesis.
For educational purposes only. Not investment advice. Consult a SEBI-registered advisor before investing.
Returns & Performance
Return on Equity (ROE)
Profit generated per ₹1 of shareholder equity
Return on Capital (ROCE)
Returns generated on total capital deployed
Oper. Profit Margin (5Y Avg)
Average operating profit margin over 5 years
Dividend Yield
Annual dividend as % of current share price
3B Blackbio Dx Limited Valuation Check
Price to Earnings (P/E)
Share price ÷ earnings per share. Lower = cheaper
Industry Avg P/E
Average P/E of all peers in this sector
Market Capitalisation
Total market value of all outstanding shares
Growth Engine
Profit Growth (Quarterly YoY)
Net profit growth vs same quarter last year
Revenue Growth (Quarterly YoY)
Revenue growth vs same quarter last year
Revenue Growth (5-Year CAGR)
Compounded annual revenue growth over 5 years
EPS Growth (5-Year CAGR)
Earnings per share growth over 5 years
Net Profit Growth (5-Year CAGR)
Compounded annual net profit growth over 5 years
Balance Sheet Health
Debt to Equity Ratio
Total debt ÷ equity. Below 0.5 = financially healthy
Interest Coverage Ratio
EBIT ÷ interest expense. Above 2.5 = can pay interest comfortably
Free Cash Flow (5-Year Total)
Cash left after capex over 5 years. Positive = self-funded growth
Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice
3B Blackbio Dx Limited Fundamental Analysis & Valuation Benchmarking
Educational evaluation of 3BBLACKBIO across key market metrics for learning purposes.
Positive Indicators
1 factors identified
Zero Share Pledging Risk
Observation: No promoter shares pledged as collateral.
Analysis: Absence of share pledging eliminates potential forced-selling pressure.
Risk Factors
1 factors identified
Limited Institutional Interest (FII+DII: 4.65%)
Observation: Low institutional participation may affect liquidity.
Analysis: Limited institutional interest may indicate size constraints or visibility issues.
3B Blackbio Dx Limited vs Healthcare Service Provider Peers
Peer Comparison - Healthcare Service Provider
Compare 3B Blackbio Dx Limited with 10 other companies in the same sector
| Company Info | Fundamental | Valuation | Profitability | Financial Health | Growth | Dividend | ||||
|---|---|---|---|---|---|---|---|---|---|---|
Company Company name | Score Bull Run comprehensive fundamental score based on 20+ metrics | Price Current trading price of the stock | Market Cap Total value of all shares in the market | P/E Price per share divided by earnings per share | ROE Net income divided by shareholder equity | ROCE Earnings before interest and tax divided by capital employed | Debt/Eq Total debt divided by total equity | Profit 5Y Average annual profit growth over 5 years | Sales 5Y Average annual sales growth over 5 years | Dividend Annual dividend per share divided by price per share |
3B Blackbio Dx Limited3B Blackbio Dx ...Selected✓ 3BBLACKBIO • 532067 | 60.3/100 | ₹1262.40₹1262 | ₹1079.13₹1079.13 | — — | — — | — — | — — | — — | — — | 0.31% |
Dr. Lal Path Labs Ltd.Dr. Lal Path La... LALPATHLAB • 539524 | 57.7/100 | ₹1901.40₹1901 | ₹28908.91₹28908.91 | 53.35Average 53.3 Average | 21.57%Excellent 21.57% Excellent | 27.62%Excellent 27.62% Excellent | 0.00Excellent 0.0 Excellent | 11.60%Good 11.60% Good | 11.81%Good 11.81% Good | 0.81% |
Vijaya Diagnostic Centre LimitedVijaya Diagnost... VIJAYA • 543350 | 67.8/100 | ₹1497.30₹1497 | ₹14307.85₹14307.85 | 76.31Average 76.3 Average | 19.74%Good 19.74% Good | 21.32%Excellent 21.32% Excellent | 0.00Excellent 0.0 Excellent | — — | — — | 0.14% |
Metropolis Healthcare LimitedMetropolis Heal... METROPOLIS • 542650 | 57.9/100 | ₹551.95₹552 | ₹11858.49₹11858.49 | 58.81Average 58.8 Average | 13.36%Average 13.36% Average | 16.80%Good 16.80% Good | 0.01Excellent 0.0 Excellent | 0.74%Average 0.74% Average | 10.52%Good 10.52% Good | 0.35% |
Thyrocare Technologies LimitedThyrocare Techn... THYROCARE • 539871 | 46.7/100 | ₹608.25₹608 | ₹8420.27₹8420.27 | 47.76Average 47.8 Average | 28.80%Excellent 28.80% Excellent | 35.47%Excellent 35.47% Excellent | 0.00Excellent 0.0 Excellent | — — | 10.88%Good 10.88% Good | 1.76% |
Krsnaa Diagnostics LimitedKrsnaa Diagnost... KRSNAA • 543328 | 31.9/100 | ₹540.20₹540 | ₹1777.47₹1777.47 | 21.62Average 21.6 Average | 10.89%Average 10.89% Average | 13.05%Average 13.05% Average | 0.55Good 0.5 Good | — — | — — | 0.50% |
Suraksha Diagnostic LimitedSuraksha Diagno... SURAKSHA • 544293 | 56.2/100 | ₹318.30₹318 | ₹1359.30₹1359.30 | 37.97Average 38.0 Average | 14.11%Average 14.11% Average | 16.82%Good 16.82% Good | 0.01Excellent 0.0 Excellent | — — | — — | 0.00% |
One Global Service Provider LimitedOne Global Serv... ONEGLOBAL • 514330 | 82.2/100 | ₹537.05₹537 | ₹1178.25₹1178.25 | — — | — — | — — | — — | — — | — — | 0.00% |
Sastasundar Ventures LtdSastasundar Ven... SASTASUNDR • 533259 | 39/100 | ₹301.45₹301 | ₹1035.54₹1035.54 | 539.34Average 539.3 Average | 0.29%Poor 0.29% Poor | -0.05%Poor -0.05% Poor | 0.04Excellent 0.0 Excellent | 16.91%Excellent 16.91% Excellent | 19.09%Excellent 19.09% Excellent | 0.00% |
49.4/100 | ₹240.00₹240 | ₹600.78₹600.78 | 20.55Average 20.6 Average | 19.92%Good 19.92% Good | 23.27%Excellent 23.27% Excellent | 0.31Excellent 0.3 Excellent | — — | — — | 0.00% | |
Aspira Pathlab & Diagnostics LimitedAspira Pathlab ... ASPIRA • 540788 | 11.9/100 | ₹93.70₹94 | ₹88.52₹88.52 | 1770.34Average 1770.3 Average | 0.51%Poor 0.51% Poor | 2.84%Poor 2.84% Poor | 0.27Excellent 0.3 Excellent | -48.50%Poor -48.50% Poor | 10.43%Good 10.43% Good | 0.00% |
Top Healthcare Service Provider Stocks
View all →By Bull Run Score
By Return on Equity
By Market Cap
- Dr. Lal Path Labs Ltd. share price28908.91 Cr
- Vijaya Diagnostic Centre Limited share price14307.85 Cr
- Metropolis Healthcare Limited share price11858.49 Cr
- Thyrocare Technologies Limited share price8420.27 Cr
- Krsnaa Diagnostics Limited share price1777.47 Cr
3B Blackbio Dx Limited PE Ratio History
Historical price-to-earnings ratio for 3BBLACKBIO — last 5 years
| Year | EPS (₹) | Price (₹) | P/E Ratio |
|---|---|---|---|
| FY 2024 | ₹37.46 | ₹1978.65 | 52.8x |
P/E = year-end price ÷ diluted EPS from annual filings. Source: NSE/BSE via Bull Run.
3B Blackbio Dx Limited Dividend History
Annual cash dividends paid by 3BBLACKBIO — dividend yield 0.31%
| Financial Year | Dividends Paid (₹ Cr) |
|---|---|
| FY 2025 | ₹2.57 Cr |
| FY 2024 | ₹2.19 Cr |
| FY 2023 | ₹4.44 Cr |
| FY 2022 | ₹15.46 Cr |
Cash dividends from annual cash flow statements. Past dividends do not guarantee future payments. Not investment advice.
3B Blackbio Dx Limited Quarterly Performance
Latest quarterly metrics for 3BBLACKBIO — revenue growth and profit growth vs same quarter last year
Revenue Growth (YoY)
N/A
Latest quarter vs same quarter previous year
Net Profit Growth (YoY)
N/A
Latest quarter net profit vs same quarter previous year
5-Year Revenue CAGR
N/A
Compounded annual revenue growth over 5 years
5-Year Profit CAGR
N/A
Compounded annual net profit growth over 5 years
3B Blackbio Dx Limited Technical Indicators
SMA 50, SMA 200, RSI and volume signals for 3BBLACKBIO — calculated from daily price history
Selling pressure is heavy — potential reversal zone.
Technical indicators are for educational purposes only. Not investment advice.
3B Blackbio Dx Limited Financial Statements
Annual income statement, balance sheet and cash flow for 3B Blackbio Dx Limited (3BBLACKBIO) — sourced from NSE/BSE filings.
Financial Results & Statements
Latest quarterly, annual and period-wise financial data for 3B Blackbio Dx Limited
About 3BBLACKBIO (3B Blackbio Dx Limited)
3B Blackbio Diagnostics Ltd is a pioneering force in the healthcare sector, dedicated to revolutionizing disease detection and management through innovative molecular diagnostic so...lutions. The company is deeply invested in designing, developing, and manufacturing cutting-edge diagnostic tools that span a wide range of critical medical fields. From the intricate complexities of infectious diseases and oncology to the nuanced landscape of human genetics and the ever-growing threat of antimicrobial resistance, 3B Blackbio is committed to providing healthcare professionals with the power to make informed decisions, ultimately improving patient outcomes. At the heart of 3B Blackbio's mission lies a comprehensive portfolio of molecular diagnostic kits, each meticulously crafted to deliver accurate and reliable results. These kits utilize advanced technologies such as qPCR-based assays, rapid lateral flow tests, and Next Generation Sequencing (NGS), ensuring a versatile approach to diagnostics. Marketed under the TRUPCR, TRUNGS, and TRURAPID brands, these solutions empower diagnostic laboratories to perform comprehensive testing on patient samples, enabling faster and more precise diagnoses. The company's commitment to innovation and quality ensures that healthcare providers have access to the most advanced tools available. 3B Blackbio Diagnostics Ltd stands as a vital partner in the fight against disease, striving to empower clinicians with the knowledge they need to provide the best possible care. By continuously pushing the boundaries of molecular diagnostics, 3B Blackbio is not only transforming the way diseases are detected and managed, but also contributing to a healthier future for all. Their dedication to innovation, accuracy, and accessibility makes them a key player in the evolving landscape of healthcare.
Company Details
Key Leadership
Corporate Events
Latest News
3BBLACKBIO Share Price: Frequently Asked Questions
What is the current share price of 3B Blackbio Dx Limited?
3B Blackbio Dx Limited (3BBLACKBIO) trades at ₹1262.40 on NSE and BSE. Market cap ₹1.08K (Cr). Educational data only.
What is the P/E ratio of 3B Blackbio Dx Limited?
3B Blackbio Dx Limited has a P/E of N/Ax vs industry average 42.23x.
What is the Bull Run score for 3B Blackbio Dx Limited?
3B Blackbio Dx Limited has a Bull Run score of 60.3/100 based on 25+ financial parameters.
Does 3B Blackbio Dx Limited pay dividends?
3B Blackbio Dx Limited has a dividend yield of 0.31%. Past dividends don't guarantee future payments.
What is the ROE of 3B Blackbio Dx Limited?
3B Blackbio Dx Limited has ROE of N/A. Higher ROE indicates better use of shareholder equity.
What is the debt-to-equity ratio of 3B Blackbio Dx Limited?
3B Blackbio Dx Limited has debt-to-equity of N/A.
Is 3B Blackbio Dx Limited a good investment?
Bull Run gives 3B Blackbio Dx Limited a score of 60.3/100. This is not investment advice — consult a SEBI-registered advisor.